Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.

Int Clin Psychopharmacol · 2018 · PMC5895133 · PMID 29189421

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

not strictly significantP =0.053so close (0.05 < p ≤ 0.1)

Otherwise, even if not strictly significant ( P =0.053), borderline co-diagnosis might be related positively to PA reduction in patients treated with asenapine, considering a more relevant decrease in its subscale scores in comorbid patients (80.0 vs. 97.1%, P =0.041).

also in 41 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.